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Abstract Ischemic cell death during a myocardial infarction
leads to a multiphase reparative response in which the dam-
aged tissue is replaced with a fibrotic scar produced by fibro-
blasts and myofibroblasts. This also induces geometrical, bio-
mechanical, and biochemical changes in the uninjured ventric-
ular wall eliciting a reactive remodeling process that includes
interstitial and perivascular fibrosis. Although the initial repar-
ative fibrosis is crucial for preventing rupture of the ventricu-
lar wall, an exaggerated fibrotic response and reactive fibrosis
outside the injured area are detrimental as they lead to pro-
gressive impairment of cardiac function and eventually to
heart failure. In this review, we summarize current knowledge
of the mechanisms of both reparative and reactive cardiac
fibrosis in response to myocardial infarction, discuss the po-
tential of inducing cardiac regeneration through direct
reprogramming of fibroblasts and myofibroblasts into
cardiomyocytes, and review the currently available and poten-
tial future therapeutic strategies to inhibit cardiac fibrosis.
Keywords Cardiac fibrosis . Myocardial infarction .
Pro-fibrotic signaling . Anti-fibrotic therapy . Cardiac
regeneration
Introduction
Heart failure (HF) is a major public health issue that affects
more than 23 million people globally (Bui et al. 2011), and
because of the aging population, its prevalence is increasing.
Most often, HF is caused by a myocardial infarction (MI).
Following an MI, up to 1 billion cardiac cells die in response
to ischemia (Laflamme and Murry 2005). The adult mamma-
lian heart has a very limited capacity to regenerate after injury,
and the lost cells are replaced by a fibrotic scar. This is follow-
ed by remodeling of the surrounding myocardium and even-
tually leads to impaired cardiac function. The remodeling pro-
cess includes thickening (hypertrophy) and stiffening
(fibrosis) of the left ventricular wall (Sutton and Sharpe 2000).
The fibrotic response after an MI can be classified into two
types of fibrosis, namely replacement and reactive fibrosis,
both of which are mediated by fibroblasts and myofibroblasts.
Replacement fibrosis, i.e. scar formation, is a pivotal process
to prevent the rupturing of the ventricular wall after an ische-
mic insult (van den Borne et al. 2010; Shinde and
Frangogiannis 2014). However, the increased mechanical
stress post-MI, together with hormonal and paracrine media-
tors, also induces the expansion of connective tissue in areas
remote to the infarction. This reactive fibrosis in the infarct
border zone and in the remote uninjured myocardium leads to
altered chamber compliance and increased ventricular stiff-
ness thereby compromising cardiac output.
In addition to its effect on cardiac contractility, both the
fibrous scar and interstitial fibrosis have been shown to inter-
fere with the normal electrical function of the heart thus pre-
disposing to arrhythmia (for a review, see Francis Stuart et al.
2015). The compact scar may serve as an insulated non-
excitable area that anchors re-entrant arrhythmia leading to
sustained ventricular tachycardia (Ripplinger et al. 2009). In
interstitial fibrosis, the non-conducting fibrillar collagen
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network between cardiomyocyte sheets might promote re-
entrant tachycardia through inducing focal ectopic activity
and through slowing or blocking of conduction (Francis
Stuart et al. 2015). Additionally, the electronic coupling of
myofibroblasts and cardiomyocytes might play a role in
fibrosis-induced arrhythmogenesis (Kohl and Gourdie
2014). Not surprisingly, cardiac fibrosis has been identified
as an autonomous risk factor in HF: it predisposes HF patients
to sudden cardiac death and increases overall mortality inde-
pendently of the ejection fraction (Gulati et al. 2013).
In this review, we discuss the roles of the various cell types
and signaling factors in regulating the repair of infarcted myo-
cardium and in promoting post-infarction pathological reac-
tive fibrosis. We review the potential of inducing cardiac re-
generation through the direct reprogramming of fibroblasts
and myofibroblasts into cardiomyocytes. We also discuss the
therapeutic opportunities for targeting fibroblasts and
myofibroblasts in order to restrict reactive fibrosis and to in-
duce cardiac regeneration.
Fibroblasts and myofibroblasts
The three main cardiac cell types with regard to cell num-
bers are cardiomyocytes, endothelial cells, and fibroblasts.
Their relative numbers probably depend on the species,
age, and gender of the subject. In particular, the percent-
age of cardiomyocytes varies between infants, young indi-
viduals, and adults. Furthermore, the lack of a specific and
comprehensive marker for fibroblasts has impeded the pre-
cise analysis of the relative abundance of the various car-
diac cell types: several putative fibroblast markers have
been described, but none of them is unique to fibroblasts,
and not all fibroblasts express the suggested marker pro-
teins (see, for example, Souders et al. 2009; Zeisberg and
Kalluri 2010; Pinto et al. 2015). According to earlier stud-
ies, fibroblasts were considered the most abundant non-
myocyte cell type, even outnumbering cardiomyocytes in
adult mammalian hearts (Banerjee et al. 2007; Krenning
et al. 2010; Zeisberg and Kalluri 2010; Deb and Ubil
2014). A recent report by Pinto et al. (2015), however,
challenges this view by showing that endothelial cells
and cardiomyocytes are the most abundant cell types in
adult murine and human hearts, whereas fibroblasts are the
third prevalent cell type in cell numbers (Fig. 1). Even
though the proportion of cardiac fibroblasts in normal
hearts thus seems to be smaller than previously described,
fibroblasts remain a central cell type with regard to post-
infarction repair and remodeling. Furthermore, in response
to injury, the fibroblast population expands and constitutes
the majority of the cells in the infarcted area during the
post-MI healing phase.
Cardiac fibroblasts are developmentally of mesenchymal
origin, and the majority of them differentiate from
epicardium-derived cells during cardiac development (see
Zeisberg and Kalluri 2010; Deb and Ubil 2014; Moore-
Morris et al. 2016). A subpopulation of fibroblasts mainly
located in the interventricular septum and in the valves is
derived from the endocardium through the endothelial-to-
mesenchymal transition (EndoMT), whereas a small propor-
tion of cardiac fibroblasts, mostly found in the right atrium, is
derived from the neural crest (Ali et al. 2014; Moore-Morris
et al. 2014, 2016). Some evidence exists that cardiac fibro-
blasts originate from circulating progenitor stem cells that are
recruited into the ventricular myocardium during postnatal life
(Visconti and Markwald 2006). Cardiac fibroblasts are
distributed throughout the heart as strands and sheets
between cardiac muscle fibers. They help to preserve the
structural integrity of the heart by maintaining the
homeostasis of the extracellular matrix (ECM), which
provides a scaffold for all cardiac cells. They also respond to
a variety of mechanical, electrical, and biochemical stimuli
and are thereby vital for normal cardiac function. For
example, cardiac fibroblasts secrete various paracrine factors
that regulate the functions of cardiomyocytes, endothelial
cells, and immune cells. Furthermore, despite their
unexcitable character, cardiac fibroblasts have also been
shown to make direct cel l-cel l interact ions with
cardiomyocytes through gap-junctional proteins, namely the
connexins (Cx40, Cx43, and Cx45), both in vitro and in vivo
(Kohl and Gourdie 2014; Ongstad and Kohl 2016). However,
the regulation and functional relevance of fibroblast-
cardiomyocyte coupling in the heart remain to be elucidated.
Fig. 1 Main cardiac cell types and their relative abundance in adult
mouse ventricles. Percentages of various cell types are from Pinto et al.
(2015). Notably, the relative abundance of each cell type is likely to be
dependent on the species, age, gender, and disease state of the
investigated subject. For example, the fibroblast population expands
after injury. Additionally, the markers used for cell type identification
have a significant effect on the cell percentages
Cell Tissue Res
After an MI, the loss of architectural integrity exposes
fibroblasts to mechanical stress, which together with specific
hormones, growth factors, and cytokines induces fibroblast
prol iferat ion, migrat ion to the injured area, and
transdifferentiation into myofibroblasts (van den Borne et al.
2010). Myofibroblasts are cells that exhibit characteristics of
both fibroblasts and smoothmuscle cells and are not present in
healthy myocardium. The most prominent characteristic of
myofibroblasts is their migratory and contracting phenotype,
which results from the expression of contractile proteins such
as α-smooth muscle actin (α-SMA) and non-muscle myosin.
They also exhibit extensive endoplasmic reticulum allowing
them to synthesize and secrete large amounts of ECM pro-
teins. Various myofibroblast markers have been described, but
they all exhibit significant overlap with other cell types (van
den Borne et al. 2010). However, α-SMA staining alone or in
combination with a fibroblast marker is a commonly used
strategy for the identification of myofibroblasts in cardiac
tissue. The protomyofibroblast, an immature form of
myofibroblast that exhibits actin stress fibers and mature
focal adhesions but that does not express α-SMA, has been
described in connection with other tissue injuries.
Protomyofibroblasts are, however, still to be identified in
infarcted myocardium.
In addition to local cardiac fibroblasts, other cell types can
transdifferentiate into myofibroblasts and might contribute to
cardiac fibrosis. Myofibroblasts derived from hematopoietic
bone-marrow-derived progenitor cells, pericytes, epithelial
cells of the epicardium (through the epithelial-to-
mesenchymal transition, EMT), and endothelial cells (through
EndoMT) have been described in cardiac tissue (Möllmann
et al. 2006; Zeisberg et al. 2007; van Amerongen et al. 2008;
Russell et al. 2011; Duan et al. 2012; Lajiness and Conway
2014; Davis and Molkentin 2014). However, the roles of
myofibroblasts derived from the various cell types and their
contribution to cardiac fibrosis are not clear and may depend
on the type of cardiac injury. Strong evidence however
suggests that the epicardium-derived resident cardiac
fibroblasts constitute the primary source of activated
fibroblasts or myofibroblasts in the ischemic heart (Ruiz-
Villalba et al. 2015) and in pressure-overload-induced fibrosis
and remodeling (Ali et al. 2014; Moore-Morris et al. 2014).
On the other hand, a recent study byKramann et al. (2015) has
shown that perivascular Gli1+ mesenchymal-stem-cell-like
cells are key contributors in aortic banding-induced ventricu-
lar fibrosis. Upon injury, these cells differentiate into
myofibroblasts, and their genetic ablation ameliorates fibrosis
and preserves cardiac function. Although their role in MI-
induced fibrosis has not been investigated, the finding that a
substantial proportion of α-SMA-expressing myofibroblasts
is derived from Gli1+ progenitors in fibrosis of various solid
organs after diverse types of injury suggests that they also play
a role in ischemia-induced cardiac injury. Taken together,
local cardiac fibroblasts seem to represent the most
important source of myofibroblasts in response to cardiac
injury, but the contribution of other cell types, such as
perivascular stem-cell-like cells, cannot be totally ruled out.
Cardiac extracellular matrix
The cardiac ECM is composed of structural, matricellular, and
adhesion proteins that not only provide a structural framework
for cardiomyocytes, but also participate in biochemical
signaling and restrict the propagation of electrical activity
(for reviews, see Dobaczewski et al. 2012; Klingberg et al.
2013). Type I and III collagens are the primary structural
proteins in the cardiac interstitium, and in addition to
providing mechanical support by stiffening the myocardial
wall, they help in transmitting the mechanical force of
contraction (Horn and Trafford 2016). Collagens are
synthesized and secreted by fibroblasts and myofibroblasts
as collagen precursors and acquire their mature fibrillar form
after proteolytic cleavage by collagen proteinases, association
with matricellular proteins, and self-assembly to fibrils.
Collagens can be further cross-linked enzymatically by lysyl
oxidases (LOX) or by a reduction in the response to the
formation of advanced glycation end-products (AGEs).
In healthy cardiac tissue, the homeostasis of collagens is
tightly regulated through the controlled synthesis of new col-
lagen and the degradation of old collagen fibers. Collagens are
degraded by a group of endopeptidases called matrix metallo-
proteinases (MMPs) whose expression and functions are
strictly controlled in order to maintain the homeostasis of
ECM degradation and synthesis (for a review, see Lindsey
et al. 2016). MMPs also participate in regulating fibrotic sig-
naling. For example, MMP9 cleaves the latent form of
transforming growth factor β (TGF-β) in vitro leading to its
activation, whereas MMP9 depletion leads to diminished fi-
brotic signaling and attenuated left ventricular fibrosis in aged
mice. TheMMPs are inhibited by a family of four endogenous
tissue inhibitors of metalloproteinases (TIMPs), all of which
are expressed in the myocardium (Vanhoutte and Heymans
2010). By inhibiting the degradation of matrix proteins,
TIMPs contribute to ECM expansion, although they have also
been suggested to regulate cardiac fibrosis in an MMP-
independent fashion through direct functions on fibroblasts
and myofibroblasts.
The dimeric glycoprotein fibronectin (FN) is expressed
by multiple cell types and regulates adhesion and migration
of cells (Klingberg et al. 2013). It consists of homologous
repeating domains and can be alternatively spliced to pro-
duce a longer protein with inserted extra domain A (EDA)
or B (EDB). The EDA-containing FN is up-regulated in
infarcted myocardium, exhibits proinflammatory functions,
and plays a critical role in promoting the myofibroblast
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phenotype (Serini et al. 1998). Deletion of the EDA domain
has also been shown to prevent pathological remodeling and
impairment of cardiac performance after an MI (Arslan et al.
2011).
Matricellular proteins are non-structural proteins of the
ECM and play major roles in regulating wound healing
and tissue repair. Their expression is dynamically con-
trolled in response to injury. Typically, they bind to the
structural ECM proteins and exert their effects by activat-
ing cell surface receptors. The central matricellular pro-
teins with established functions in the post-MI healing
response include thrombospondins (TSPs), tenascins,
periostin, osteopontin, and the CCN family of proteins
(for an extensive review, see Frangogiannis 2012). TSPs
are a family of five stress-inducible secreted glycoproteins
that underlie tissue remodeling. TSP-1 and TSP-4 gene
expression is up-regulated in both early and late stages
of post-MI remodeling correlating with echocardiographic
parameters and natriuretic peptide gene expression and
thereby reflecting the degree of remodeling (Mustonen
et al. 2008, 2012, 2013). TSP-1 exhibits pro-fibrotic ef-
fects through the direct activation of TGF-β but has also
been suggested to play a role in preventing the expansion
of the infarction (Frangogiannis 2012; Mustonen et al.
2013). The post-MI healing process is impaired in
TSP-1 knock-out mice because of defective myofibroblast
transdifferentiation and insufficient collagen production.
In contrast, the evidence indicates a cardioprotective role
for TSP-4: deletion of TSP-4 sensitizes mice to cardiac
maladaptation, whereas transgenic mice with inducible
cardiac-specific TSP-4 overexpression are protected from
myocardial injury (Lynch et al. 2012).
Connective tissue growth factor (CTGF, also known as
CCN2), is a key mediator of ECM production under path-
ological fibrotic conditions (Frangogiannis 2012). It pro-
motes the TGF-β-induced excessive production of ECM,
and its expression is rapidly up-regulated in fibroblasts
after the exposure of cells to various growth factor stim-
uli. Mice overexpressing CTGF exhibit pronounced cardi-
ac fibrosis in response to pressure overload. Moreover,
monoclonal antibody against CTGF protects from adverse
cardiac remodeling and left ventricle dysfunction in mice
subjected to pressure overload (Szabo et al. 2014).
Tenascin C belongs to the tenascin family of highly con-
served glycoproteins (see Frangogiannis 2012). It is not
expressed in the healthy adult heart, but in response to
MI, its expression is markedly and transiently up-
regulated in fibroblasts in the border zone between in-
farcted and uninjured myocardium. Deletion of tenascin
C protects from adverse remodeling and fibrosis of the
noninfarcted myocardium suggesting that tenascin C
plays an important role in mediating reactive fibrosis
(Nishioka et al. 2010).
Replacement fibrosis after MI: phases and repair vs.
remodeling
Necrotic cardiomyocyte death induced by oxygen depletion
during an MI evokes a sequence of events that aims at
preventing further damage and rupture of the ventricular wall
by preserving the remaining cells and by replacing the dead
cells. Teleostean fish, newts, and embryonic and neonatal ro-
dents are able fully to regenerate an injured area within the
myocardium (Becker et al. 1974; Poss et al. 2002; Porrello
et al. 2011). In cardiac regeneration, the injured area is initially
replaced by a fibrin clot, followed by replacement first with a
temporary collagen-based scar and subsequently with normal
myocardial tissue. The complex process involves a tightly
control led inflammatory response, emergence of
myofibroblasts, induction of cardiomyocyte proliferation,
and neovascularization of the regenerating tissue (Jopling
et al. 2010; Kikuchi et al. 2010; Gonzalez-Rosa et al. 2012;
Aurora et al. 2014). The regenerative capacity of neonatal
rodents is gradually lost during the first week of postnatal life,
after which little or no regeneration occurs (Porrello et al.
2011). This is because of the incapability of postnatal
cardiomyocytes to re-enter the cell cycle and proliferate.
Therefore, in adult mammals, the dead cells are replaced with
a permanent collagenous scar instead of new cardiac muscle
tissue. The healing process after an MI can be divided into
three partially overlapping phases: the inflammatory phase,
the proliferative phase, and the maturation phase (Table 1).
The initial inflammatory phase is triggered by massive ne-
crotic cell death in the infarct area (for a review, see
Frangogiannis 2014). As interstitial fibroblasts, endothelial
cells, and resident cardiac mast cells are more resistant to
ischemic injury than are cardiomyocytes, they have been pro-
posed to function as effector cells triggering the post-MI in-
flammatory reaction (Shinde and Frangogiannis 2014).
Cardiac fibroblasts produce MMPs that degrade the ECM
allowing cell migration into the injured area. Tissue injury
activates innate immune signaling, and secretion of
chemokines induces leukocyte infiltration into the injured area
(Frangogiannis 2014). The CXC chemokines which have a
Glu-Leu-Arg (ELR) signature sequence upstream of the
CXC motif (ELR+ CXC chemokines) are known to recruit
primarily neutrophils, whereas chemokines from the CC sub-
family play a role in recruiting marcophages. These inflam-
matory cells clear the dead cells and ECM fragments from the
infarcted area allowing its repopulation with migrating and
proliferating immune cells and, in the later phase,
myofibroblasts. Marked increases in the cardiac expression
of the proinflammatory cytokines, namely tumor necrosis fac-
tor (TNF, formerly known as TNFα), interleukin 1 β (IL-1β),
and interleukin 6 (IL-6), have been reported in experimental
models of MI (see Frangogiannis 2014). Because of their
pleiotropic properties and effects on several cell types, their
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exact functional roles are, however, not well characterized. IL-
1 is known to regulate the fibroblast phenotype and may be
responsible for delaying fibroblast conversion to
myofibroblasts until the infarction area is cleared and ready
for the deposition of new ECM (Saxena et al. 2013).
Repression of inflammation during the transition from the
inflammatory phase to the proliferative phase is not well char-
acterized but might involve inhibitory molecules (so-called
STOP signals) and the activation of pathways that suppress
inflammation (Frangogiannis 2014).
As the proinflammatory signaling is suppressed, the num-
ber of inflammatory cells decreases through apoptotic cell
death, and profibrotic signaling takes over (Frangogiannis
2014). At the beginning of the proliferative phase, fibroblasts
become the dominant cell type in the infarct area and adopt a
proliferative, migratory, and secretory myofibroblast pheno-
type (Shinde and Frangogiannis 2014). Infiltration of the in-
jured area with myofibroblasts takes place in all species and
experimental models of myocardial injury, regardless of their
regenerative capacity. The expression and secretion of ECM
proteins by fibroblasts and myofibroblasts start from the in-
farct border zone and progress toward the core infarct area as
the cells migrate along the newly synthesized ECM matrix
(van den Borne et al. 2010). Myofibroblasts produce large
amounts of interstitial collagens (initially type III and later
on, during the infarct healing, type I collagen). Collagen de-
position is crucial for increasing tensile strength and
preventing ventricular wall rupture. In addition to ECM struc-
tural proteins, myofibroblasts secrete increased amounts of
FN, particularly EDA-FN, and various matricellular proteins,
such as TSPs and tenascin C, which further promote
myofibroblast migration and participate in regulating the
healing response (Frangogiannis 2012). Furthermore, angio-
genic signaling stimulates the proliferation and infiltration of
endothelial cells and leads to the establishment of a microvas-
cular network to the infarct area (Jaffer et al. 2006; Deb and
Ubil 2014; Frangogiannis 2014); this network is crucial for
supplying the myofibroblasts with enough oxygen and nutri-
ents during the repair process.
Following the establishment of a collagen-based ma-
trix at the infarct site, the growth factors and
matricellular proteins promoting the survival and activi-
ty of myofibroblasts are depleted (van den Borne et al.
2010; Shinde and Frangogiannis 2014). In response, the
majority of myofibroblasts are removed from the scarred
area, possibly through apoptosis. Moreover, the vascular
cells die, and the temporary microvasculature is
disintegrated. Whether active inhibitory signaling is in-
volved in suppressing the fibrotic response is unclear.
During the maturation phase of MI, collagen turnover
by the remaining myofibroblasts continues, and type
III collagen is replaced with type I collagen. Type I
collagen is further modified by LOX-catalyzed cross-
linking. The expression of all four LOX isoforms is
increased in the infarct area and in the border zone at
3–7 days post-MI (Gonzalez-Santamaria et al. 2016).
This correlates with significant accumulation of mature
collagen fibers and extensive remodeling, and LOX in-
hibition with a pharmacological inhibitor or a neutraliz-
ing antibody reduces infarct expansion resulting in im-
proved cardiac function at 28 days post-MI (Gonzalez-
Santamaria et al. 2016). Cross-linking of the collagen
fibers leads to increased tensile strength and contraction
of the scar, which alters the geometry of the chamber
and contributes to remodeling in the remote areas of the
ventricular wall (van den Borne et al. 2010). In a nor-
mal wound healing response, all myofibroblasts are
cleared from the scarred area, but in the heart, they
have been found to persist in the infarct scar even de-
cades after the insult (Willems et al. 1994). The reason
for the continuous myofibroblast presence in the infarct
scar is not known but is possibly necessary for the
continuous maintenance of the ECM in the continuously
contracting environment (van den Borne et al. 2010).
Reactive fibrosis: remodeling of remote myocardium
Most often it is not the necrotic cardiomyocyte loss duringMI
that causes heart failure but the subsequent remodeling of the
non-infarcted left ventricular wall. In pathological remodel-
ing, the fibroblast-mediated expansion of the ECM is accom-
panied by the hypertrophic growth of cardiomyocytes as the
cells try to compensate for the increased workload by growing
in size in order to increase cardiac function and decrease ven-
tricular wall tension (Heineke and Molkentin 2006). The in-
creased thickness caused by cardiomyocyte hypertrophy and
stiffness attributable to excessive cross-linked collagen and
the tonic contraction of fibrous tissue mediated by
myofibroblasts compromise the diastolic function of the heart
(Weber et al. 2013). This remodeling process is progressive
and eventually leads to the development of heart failure.
The exact mechanisms and regulation of reactive fi-
brosis are unclear, and systematic studies examining the
characteristics of fibroblasts in the non-infarcted myo-
cardium are lacking (Shinde and Frangogiannis 2014).
One promoting factor is the increased mechanical stress
in the non-infarcted left ventricular wall; this stress also
induces the activation of latent TGF-β in the non-
infarcted myocardium. In addition, the persisting activat-
ed myofibroblasts in the infarct scar continue to secrete
pro-fibrotic factors that might traverse to the remote
areas of the myocardium inducing activation and prolif-
eration of local fibroblasts and increased collagen depo-
sition in the interstitial compartment (interstitial fibrosis)
and in the adventitia of coronary vessels (perivascular
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fibrosis; Weber et al. 2013). Pro-fibrotic factors initiat-
ing and sustaining the reactive fibrotic response are de-
scribed in the next section.
Whereas interstitial fibrosis stiffens the myocardium and
thereby leads to diastolic and systolic dysfunction, reactive
fibrosis in the adventitia of the coronary arteries and arterioles
(perivascular fibrosis) can cause narrowing of the vessel lu-
men and has been associated with impaired coronary blood
flow (Dai et al. 2012). This might decrease the oxygen supply
to the myocardium thereby compromising the survival of
cardiomyocytes and predisposing them to ischemic cell death.
Pro-fibrotic signaling in myocardium
The function of cardiac fibroblasts and the fibrotic response in
the myocardium are regulated by ECM through matricellular
proteins (as described above) and through direct ECM-
fibroblast connections mediated by transmembrane receptors
called integrins (for a review, see Chen et al. 2016). In addi-
tion, numerous hormonal, paracrine, and autocrine factors
play a critical role in controlling post-MI fibrosis (Fig. 2).
TGF-β is probably the best-characterized pro-fibrotic growth
factor (Dobaczewski et al. 2011; Kong et al. 2014). Three
TGF-β isoforms (1, 2, and 3) exist in mammals, but our
knowledge is mainly limited to TGF-β1. In vitro, TGF-β
induces myofibroblast transdifferentiation and enhances
ECM protein synthesis (Desmouliere et al. 1993). Plenty of
evidence also exists for its profibrotic role in vivo as obtained
by using both cardiac overexpression and loss-of-function ap-
proaches (see Kong et al. 2014). In the healthy heart, TGF-β is
present as a latent complex that cannot associate with and
activate its receptors but that can be rapidly released and acti-
vated in response to reactive oxygen species (ROS) genera-
tion, the activation of proteases, mechanical strain, and the
induction of matricellular proteins such as TSPs (Buscemi
et al. 2011; Frangogiannis 2014). Additionally, TGF-β is syn-
thesized and secreted by platelets, leukocytes, and fibroblasts
in the infarcted myocardium (Dobaczewski et al. 2011).
TGF-β1 exerts its effects through binding to its constitu-
tively active tyrosine kinase receptor, namely type II TGF-β
receptor (TβRII), at the cell surface. Ligand binding to TβRII
recruits the type I receptor (TβRI, also known as ALK5) and
induces its transphosphorylation. The intracellular signaling
routes include the Smad-dependent regulation of gene expres-
sion and the Smad-independent activation of signaling cas-
cades including mitogen-activated protein kinase (MAPK)
signaling and signaling through the small GTPase Rho. In
particular, signaling through TGF-β-activated kinase
(TAK1) and p38MAPK has been implicated in myofibroblast
Fig. 2 Central pro-fibrotic signaling factors and their effects on fibroblast
proliferation, transdifferentiation to myofibroblasts, and extracellular
matrix deposition (α-SMA α-smooth muscle actin, CTGF connective
tissue growth factor, EDA-FN extra-domain-A-containing fibronectin,
MMPs matrix metalloproteinases, TGF-β transforming growth factor β,
TIMPs tissue inhibitors of matrix metalloproteinases, TSPs
thrombospondins)
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transdifferentiation, and pharmacological p38 MAPK inhibi-
tion is protective against cardiac fibrosis in a rat model of MI
(see Lighthouse and Small 2016). Strong evidence also sup-
ports an important role for Smad3-dependent TGF-β signal-
ing in the development of post-MI fibrosis; Smad3 null ani-
mals have been reported to exhibit less dilative remodeling
and attenuated diastolic dysfunction, despite similar infarct
sizes (Bujak et al. 2007). This has been attributed to a
Bhypofunctional^ phenotype of infiltrated fibroblasts
(increased proliferation accompanied with impaired
myofibroblast transdifferentiation and decreased ECM
protein deposition; Dobaczewski et al. 2010).
The octapeptide angiotensin II (Ang II) is the central
signaling molecule of the renin-angiotensin system (RAS)
with regard to cardiac fibrosis. Its immediate in vivo effects
include vasoconstriction and increased blood pressure, but
it also has direct remodeling-inducing effects on various
cardiac cell types (see Leask 2015). At the cellular level,
Ang II promotes fibroblast proliferation, myofibroblast
transdifferentiation, ECM turnover, and the secretion of
proinflammatory cytokines and growth factors. It is
expressed and activated by fibroblasts, myofibroblasts, and
macrophages in the heart, and by acting on its type I re-
ceptor (AT1 receptor), it up-regulates the expression of
TGF-β and IL-6 in cardiomyocytes, fibroblasts, and
myofibroblasts. Both Ang II and TGF-β synthesized and
secreted at the infarction site have been suggested to play a
role in the development of reactive fibrosis in the non-
infarcted myocardium (Weber et al. 2013). They may be
able to traverse from the infarcted area to the peri-infarct
and to remote areas and might induce fibroblast prolifera-
tion and collagen synthesis and secretion in the non-
infarcted area. However, no direct evidence of this phenom-
enon has been presented.
The RAS also promotes fibrosis in an Ang II-independent
manner. One key component of the local RAS in the heart is
the (pro)renin receptor (PRR; Bader 2010). By binding to
PRR, prorenin becomes catalytically active, thus inducing
the generation of Ang II. However, renin or prorenin binding
to PRR also induces the activation of intracellular signaling
that results in the up-regulation of pro-fibrotic genes (Nguyen
2011). In normal rats, PRR gene delivery into the heart in-
duces deleterious myocardial fibrosis associated with the in-
creased expression of various pro-fibrotic genes, such as
TGFβ1, CTGF, collagen 1α1, plasminogen activator inhibi-
tor-1, and fibronectin-1, indicating that PRR plays a critical
role in hearts undergoing the fibrotic remodeling process
(Moilanen et al. 2012). The effects of PRR overexpression
are not antagonized by the AT1 receptor antagonist losartan
indicating an Ang II-independent mechanism for PRR-
mediated myocardial remodeling.
Endothelin-1 (ET-1) is predominantly produced by endo-
thelial cells, but other cardiac cell types (fibroblasts,
cardiomyocytes, and macrophages) can also synthesize and
secrete it (Rodriguez-Pascual et al. 2014; Leask 2015). ET-1
is a potent pro-fibrotic mediator that seems to act downstream
of TGF-β and Ang II, as both of them induce its secretion
(Leask 2010; Kong et al. 2014). Similarly to Ang II and
TGF-β, ET-1 enhances the proliferation of cardiac fibroblasts
and promotes ECM protein synthesis in vitro (Kong et al.
2014). Cardiac-specific overexpression of ET-1 induces fibro-
sis, and ET-1 antagonism has been shown to reduce fibrosis in
an animal model of MI (Oie et al. 2002; Mueller et al. 2011).
However, clinical trials with ET receptor antagonists have not
shown beneficial effects on cardiac fibrosis or remodeling
(Kohan et al. 2012).
Other factors that are known to participate in pro-fibrotic
signaling and thereby potentially to promote cardiac fibrosis
include ROS, fibroblast growth factor (FGF), and platelet-
derived growth factor (PDGF; Leask 2015). PDGF has been
suggested to play a role in the proliferation and maturation
phases of MI healing: elevated levels of PDGF-A, PDGF-D,
and PDGF receptors have been detected in endothelial cells,
macrophages, and myofibroblasts in a murine model of MI
from post-MI days 3–7 onward (Zhao et al. 2011).
An emerging concept in the regulation of cardiac fibrosis is
the involvement of non-coding RNAs. Several microRNAs
(miRNAs) that are thought either to promote (miR-21, miR-
34, miR-199b, miR-208) or to inhibit (miR-1, miR-26a, miR-
29, miR-101, miR-122, miR-133/miR-30, miR-133a, miR-
214) cardiac fibrosis have been identified (for reviews, see
Thum 2014; Piccoli et al. 2016). Of the anti-fibrotic
miRNAs, miR-1 and miR-133 are of particular interest as they
have been successfully used for the direct reprogramming of
fibroblasts to cardiomyocytes in combination with cardiac
transcription factors or miR-208 and miR-499 (see the next
section). miR-1 and miR-133 attenuate left ventricular fibrosis
in experimental pressure overload (Matkovich et al. 2010;
Karakikes et al. 2013). Both of them also play a role in cardiac
hypertrophy (Care et al. 2007; Karakikes et al. 2013).
Whereas the anti-fibrotic effect of miR-1 has been suggested
to be indirect (Thum 2014), miR-133 has been shown directly
to suppress collagen expression, both in vitro and in vivo
(Shan et al. 2009; Castoldi et al. 2012). Furthermore, the
miRNAs of the lethal-7 (Let-7) family have recently been
shown to play an important role in post-MI remodeling
(Tolonen et al. 2014). Inhibition of Let-7c with an intrave-
nously administered antagomir attenuates myocardial fibrosis
and maintains the left ventricular systolic function in mice
after ligation of the left anterior descending coronary artery.
The Let-7 family of miRNAs also function as suppressors of
stem cell pluripotency by regulating the expression of
pluripotency genes Oct4 and Sox2 (Roush and Slack 2008).
Let-7 inhibition increases the expression of pluripotency
genes in cardiac fibroblasts and in the hearts of adult mice,
suggesting that the inhibition of Let-7 is a potential approach
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for inhibiting detrimental post-MI fibrosis (Tolonen et al.
2014). Long non-coding RNAs (lncRNAs) and circular
RNAs are additional, more recently described types of non-
coding regulatory RNA molecules. However, their roles in
cardiac fibrosis are however still mostly unclear (Piccoli
et al. 2016).
Fibroblast reprogramming - harnessing fibrosis
to induce regeneration
As the optimal therapeutic goal for post-MI treatment would
be to reduce fibrosis and to induce the regeneration of the
myocardial tissue through the generation of novel
cardiomyocytes, the fibroblasts and myofibroblasts that in-
vade the injured area in order to replace the damaged tissue
with a scar represent an attractive target for therapeutic inter-
vention. Indeed, because of the injury-induced fibroblast-
myofibroblast transdifferentiation process, these cells might
represent a population of plastic cells that can be more easily
reprogrammed further into another cell type. The direct
reprogramming of fibroblasts/myofibroblasts into induced
cardiomyocyte-like cells (iCMs) with the help of cardiac tran-
scription factor overexpression was first reported by Ieda et al.
in 2010 (Ieda et al. 2010), and since then, several groups have
reported successful cardiac reprogramming with various strat-
egies, both in vitro (Table 2) and in vivo (Table 3; for reviews,
see, for example, Srivastava and Berry 2013; Fu and
Srivastava 2015; Sahara et al. 2015; Srivastava and Yu 2015).
The majority of in vitro reprogramming studies have
exploited the forced overexpression of cardiac transcription
factors to induce a direct conversion from fibroblasts to in-
duced cardiomyocytes without passing through a pluripotent
or progenitor state (see Table 2 for details and references),
whereas some have combined a transient induction by
Yamanaka reprogramming factors with subsequent culture in
cardiogenic medium to produce iCMs through a progenitor
cell stage (Efe et al. 2011; Talkhabi et al. 2015).
Furthermore, cardiac reprogramming with the help of
miRNAs alone or in combination with transcription factor
overexpression has been reported (Nam et al. 2013;
Jayawardena et al. 2014; Muraoka and Ieda 2014;
Jayawardena et al. 2015; Zhao et al. 2015). The epigenetic
reprogramming of fibroblasts into iCMs seems to be stable,
as withdrawal of the transcription factors used after 10 days
does not affect the morphology or Ca2+ oscillations of the
resulting iCMs (Addis et al. 2013).
Direct comparison of reprogramming efficiency between
the different approaches is difficult because of differences in
the experimental setup and the outcome measures used for
cardiomyocyte classification. In particular, the time point
and the criteria used for classifying cells as iCMs have a dra-
matic effect on the reported reprogramming efficiency.
Classification based on cardiac protein expression (cardiac
troponin T [cTnT] or cardiac α-actinin) results in significantly
higher reported efficiency than classification by using a func-
tional measure such as Ca2+ activity combined with a cardiac-
specific reporter or than classification based on the presence of
sarcomeres. Nevertheless, certain conclusions with regard to
reprogramming efficiency can be drawn from the plethora of
studies published. When Ca2+ activity was used as the out-
come, the combination of Hand2, Nkx2.5, Gata4,Mef2c, and
Tbx5 was found to be >50-fold more efficient than the three-
factor combination of Gata4, Mef2c, and Tbx5 (Addis et al.
2013), suggesting that additional transcription factors, al-
though not necessary for the expression of cardiac proteins
such as cTnT, might be important in the maturation of iCMs
to functional cardiomyocytes. The highest reprogramming ef-
ficiency reported, with cTnT+ cells used as a measure of
iCMs, is a remarkable 67 % (Zhao et al. 2015). This was
achieved by the overexpression of four cardiac transcription
factors (Gata4,Hand2,Mef2c, Tbx5) and two miRNAs (miR-
1, miR-133) combined with the pharmacological inhibition of
TGF-β. Inhibition of fibrotic signaling with TGF-β or Rho-
assoc ia t ed k inase (ROCK) inh ib i to r s improves
reprogramming efficiency, as does the overexpression of
Akt/protein kinase B (Ifkovits et al. 2014; Zhao et al. 2015;
Zhou et al. 2015).
Most of the in vitro studies have been carried out with
primary fibroblasts isolated from mice, but successful cardiac
reprogramming has also been reported with primary fibro-
blasts isolated from rats, dogs, and humans (Table 2).
Human fibroblasts have proven to be more resistant to
reprogramming than murine fibroblasts: the successful cardiac
reprogramming of human fibroblasts into iCMs requires more
transcription factors than reprogramming of murine fibro-
blasts, and the process is slower and less efficient with human
cells compared with murine cells. The origins of the fibro-
blasts also affect reprogramming efficiency, and cardiac fibro-
blasts are more easily converted to iCMs than other fibroblasts
(Ieda et al. 2010; Addis et al. 2013; Palazzolo et al. 2016).
This is in agreement with the report showing that cardiac
fibroblasts express a number of cardiogenic genes such as
transcription factors Gata4, Tbx20, Tbx5, Nkx2-5, Hand2,
and Mef2c at significantly higher levels than tail fibroblasts
(Furtado et al. 2014). At least a subpopulation of cardiac fi-
broblasts thus seems to be Bprimed^ for reprogramming.
The reprogrammed iCMs consist of all three major CM
subtypes: pacemaker, atrial, and ventricular (Nam et al.
2014). However, the phenotype of iCMs produced by direct
reprogramming in vitro resembles that of immature
cardiomyocytes with spontaneous Ca2+ oscillations and con-
tractions (Sahara et al. 2015). This is consistent with the im-
mature phenotype of cardiomyocytes derived from embryonic
stem cells (ESCs) or induced pluripotent stem cells (iPSCs;
Gherghiceanu et al. 2011). With regard to clinical
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applications, an immature phenotype can be considered to
increase the risk of arrhythmia, and therefore strategies to
promote the maturation of iCMs are needed. The biomechan-
ical and biochemical environment in the myocardium might,
however, promote the maturation of iCMs, thereby reducing
the r isk of proarrhythmia. Most in vivo cardiac
reprogramming studies have utilized lineage tracing to dem-
onstrate the origin of in vivo reprogrammed iCMs and a strat-
egy of injecting viral vectors for cardiac transcription factors
or miRNAs immediately after the induction of MI with coro-
nary artery ligation (see Table 3 for details and references).
Although the numbers of reprogrammed cells detected in the
injured area or in the border zone have been quite modest, the
iCMs generated in vivo exhibit morphology resembling ma-
ture cardiomyocytes and seem to make connections to endog-
enous cardiomyocytes (Song et al. 2012; Qian et al. 2012; Ma
et al. 2015). The environmental clues present in the heart and
the epigenetic state of cardiac fibroblasts thus indeed seem to
support the maturation and proper electrical coupling of iCMs.
Furthermore, the functional improvements observed in re-
sponse to in vivo reprogramming afterMI are more substantial
than expected taking into account the relatively modest num-
ber of iCMs generated. However, this is not surprising, as
intramyocardial Gata4 gene transfer has been shown to sig-
nificantly reduce infarct size and improve ejection fraction in a
rat model of MI (Rysä et al. 2010). The cardioprotective
mechanisms of Gata4 overexpression include the induction
of myocardial angiogenesis, the inhibition of apoptosis, and
the recruitment of c-Kit+ cardiac progenitor cells.
As an alternative approach, recent reports describe three
different strategies for reprogramming fibroblasts into induced
cardiovascular progenitor cells (iCPCs) in vitro (Table 4).
When grown under cell culture conditions that favor cardio-
myocyte generation, these iCPCs differentiate into
cardiomyocytes (Pratico et al. 2015; Lalit et al. 2016; Zhang
et al. 2016). The iCPCs also differentiate into cardiomyocytes,
endothelial cells, and vascular smooth muscle cells in vivo
after cell transplantation to infarcted myocardium (Lalit et al.
2016; Zhang et al. 2016). The advantage of reprogramming
fibroblasts to progenitor cells rather than directly to iCMs lies
in the ability of iCPCs to proliferate allowing the expansion of
the cell population before differentiation into iCMs (Lalit et al.
2016; Zhang et al. 2016). Whether reprogramming to iCPCs
can be achieved in vivo and how the proliferation and differ-
entiation can be controlled remain to be investigated.
Effect of current HF drugs on fibrosis
Current HF treatment recommendations are based on RAS
inhibition and β adrenergic receptor antagonists, supplement-
ed with mineralocorticoid/aldosterone receptor antagonists,
ivabradine, and/or digoxin as necessary (McMurray et al.
2012). In cases with a diagnosis or a high risk of coronary
artery disease, cholesterol-lowering drugs are included in the
regimen. Despite advances in therapy, the mortality rates for
HF are higher than those for many cancers: 40–60 % of pa-
tients die within 5 years of diagnosis (see Bui et al. 2011).
Although none of the presently available drugs are able to
reverse post-infarction remodeling, some have been shown
to exhibit anti-fibrotic properties, both in vitro and in vivo,
and their clinical efficacy in the treatment of HFmay therefore
be partly attributable to the inhibition of pathological
remodeling.
Because of the well-established role of Ang II in promoting
cardiac fibrosis through the AT1 receptor-mediated up-regula-
tion of TGF-β1 expression, angiotensin-converting enzyme 1
(ACE1) inhibitors and AT1 receptor blockers (ARBs) unsur-
prisingly inhibit cardiac remodeling and fibrosis in various
experimental models (reviewed in Rosenkranz 2004; Porter
and Turner 2009; Weber et al. 2013). In addition to inhibiting
the AT1 receptor-mediated TGF-β up-regulation, ARBs have
been shown to up-regulate the expression of another ACE
isoform, ACE2, which hydrolyses angiotensin II into angio-
tensin [1–7] (see Weber et al. 2013). Signaling through the
ACE2—angiotensin [1–7]—Mas receptor axis is
cardioprotective, and ARBs have thus been suggested to have
additional benefits over ACE inhibitors (Weber et al. 2013).
However, early treatment with ARB losartan has also been
shown to aggravate cardiac remodeling in a rat model of MI
by inducing apoptosis and fibrosis in the peri-infarct area
(Serpi et al. 2009). The timing of ARB treatment may thus
be critical in order to achieve optimal results.
In contrast to cardiomyocytes with predominant β1 adren-
ergic receptor-mediated signaling, cardiac fibroblasts express
mainly β2 adrenergic receptors, and β1 receptor-mediated sig-
naling plays only a minor role (Porter and Turner 2009;
Aranguiz-Urroz et al. 2011; Carter et al. 2014). Stimulation
of β2 receptors in cardiac fibroblasts has been linked to the
increased proliferation of cardiac fibroblasts and the up-
regulation of IL-6, and these effects can be blocked with
non-selective or β2 receptor-selective antagonists, but not
with antagonists selective for β1 receptors, suggesting that
the inhibition of β2 receptors is beneficial in reducing fibrosis
(see Porter and Turner 2009). However, the effects of IL-6
down-regulation on cardiac remodeling have not been eluci-
dated, and temporal control might be critical for a beneficial
effect (see Frangogiannis 2014). Theβ receptor blockers most
frequently prescribed for secondary prevention after MI are
β1-selective, which has been hypothesized to overlook the
potential benefits of blocking β2 receptor-mediated signaling
in cardiac fibroblasts (Porter and Turner 2009).
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, namely statins, are effective and
widely used for both primary and secondary prevention
of ischemic cardiovascular events because of their
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cholesterol-lowering effects. Additionally, increasing evi-
dence suggests that they exhibit anti-remodeling proper-
ties, which contribute to their beneficial clinical effects.
Under in vitro conditions, statins have been shown to di-
rectly inhibit cardiac fibroblast proliferation and migration,
fibroblast-myofibroblast transdifferentiation, and ECM
turnover, all of which are expected to confer beneficial
effects in the myocardial remodeling process (for a
review, see Porter and Turner 2009). Statins have also been
described to exhibit anti-fibrotic effects in vivo, for exam-
ple, in animal models of myocardial infarction (Sun et al.
2015; Hayashidani et al. 2002) and metabolic syndrome
(Hermida et al. 2013). All in all, statins and other cardio-
vascular drugs currently in use are, however, not efficient
enough in blocking the progression of pathological fibrosis
and remodeling, and therefore, new and more efficient
anti-fibrotic drugs are needed.
Concluding remarks and future prospects
ECM homeostasis in the myocardium is essential for
normal cardiac function. An efficient reparative scarring
process after an MI is also of critical importance for
maintaining the structural integrity of the ventricular
wall. However, the progressive reactive fibrosis elicited
by biomechanical and biochemical changes in the non-
infarcted myocardium after an ischemic injury plays a
major role in the development of HF. Cardiac fibro-
blasts and myofibroblasts therefore represent attractive
cellular targets for the development of treatments aimed
at inhibiting pathological post-infarction remodeling.
However, such therapies should specifically inhibit the
reactive fibrosis without interfering with the initial re-
parative scarring process.
In order to stop the reactive fibrosis that contributes to the
progression of HF, two strategies can be taken: the inhibition
of pro-fibrotic signaling and the activation of anti-fibrotic
pathways. As TGF-β plays a central role in promoting fibro-
blast proliferation, myofibroblast transdifferentiation, colla-
gen deposition, and myofibroblast survival, the inhibition of
TGF-β signaling is a promising approach for inhibiting fibro-
sis. However, in order not to interfere with the scar formation
at the site of the injury, TGF-β inhibition should be temporally
controlled and initiated only in the post-healing phase after
MI. This is supported by the in vitro observation that the
inhibition of TGF-β signaling by the overexpression of c-
Ski induces the reversal of the myofibroblast phenotype
(Cunnington et al. 2011), suggesting that TGF-β inhibition
can be used to convert myofibroblasts back to quiescent fibro-
blasts once the scar is formed. Of note, the inhibition of
TGF-β has been linked to aortic aneurysm progression and
complications in mice (Wang et al. 2010), emphasizing that
the approach is not risk-free. In addition, targeting EDA-FN
might provide a means to selectively inhibit reactive fibrosis:
EDA-FN knockout mice exhibit reduced reactive fibrosis in
the remote non-infarcted myocardium, whereas the level of
reparative fibrosis is unaffected (Arslan et al. 2011).
Moreover, PRR represents an interesting drug target, and
PRR blockers could be combined with ARBs to allow more
complete myocardial protection and to prevent the deleterious
Ang-II-independent actions of renin that are not inhibited by
renin inhibitors (Moilanen et al. 2012). Interesting observa-
tions also include the anti-fibrotic effects of neuregulin 1
(NRG1), a growth factor that plays a role in cardiac develop-
ment and also mediates cardiac regeneration (Kim et al. 2012;
Galindo et al. 2014; Harvey et al. 2016). In a swine model of
MI, intravenous NRG1 treatment initiated at 1 week post-
infarction suppressed fibrosis and improved cardiac function
(Galindo et al. 2014). In vitro studies with murine and rat
primary cardiac fibroblasts suggest that the anti-fibrotic mech-
anism of NRG1 is mediated through inhibition of TGF-β
signaling and myofibroblast transdifferentiation. Other puta-
tive therapeutic strategies to inhibit pro-fibrotic signaling in-
clude LOX inhibition,Wnt inhibition, and histone deacetylase
inhibition (Hermans et al. 2012; Schuetze et al. 2014;
Gonzalez-Santamaria et al. 2016).
The second strategy to limit reactive post-MI fibrosis by
activating anti-fibrotic signaling pathways has gained less
attention, and the signaling pathways that restrict excessive
fibrosis in physiological homeostasis represent an insuffi-
ciently investigated area. Natriuretic peptide A (NPPA,
ANP) and B (NPPB, BNP) have emerged as important can-
didates for the development of therapeutic agents for heart
failure (Lee and Burnett 2007). Their secretion is markedly
up-regulated in HF, and they exhibit important autocrine,
paracrine, and endocrine cardioprotective and anti-
remodeling activities that are mediated through the guanylyl
cyclase-A (GC-A) receptor and the activation of cyclic gua-
nosine monophosphate (cGMP) in target cells (Ruskoaho
1992; Lee and Burnett 2007). In particular, strong evidence
supports an anti-fibrotic role for BNP. In cultured fibroblasts,
BNP decreases collagen synthesis and up-regulates MMP
expression (Tsuruda et al. 2002). Mice lacking the BNP gene
have normal-sized hearts but increased ventricular fibrosis
(Tamura et al. 2000). Furthermore, local intramyocardial
BNP gene delivery improves cardiac function and attenuates
post-MI and Ang II-induced fibrosis and adverse remodeling
(Moilanen et al. 2011). The enhancement of BNP-mediated
effects in the heart would thus be an attractive strategy to
inhibit cardiac fibrosis. Another approach for enhancing
anti-fibrotic signaling through activating cGMP-mediated
pathways is by the inhibition of cGMP-degrading enzymes,
the phosphodiesterases (PDEs). PDE5 inhibitors are widely
used for erectile dysfunction, and more recent evidence high-
lights their additional beneficial effects, including the
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inhibition of fibrosis, in the heart (Kass 2012; Gong et al.
2014; Corinaldesi et al. 2016).
More ambitious is the aim of reversing reparative fibrosis at
the infarct site to induce regeneration of the cardiac muscle.
The plasticity of cardiac fibroblasts and myofibroblasts and
their abundance in the injured area make them a suitable
starting cell population for the generation of de novo
cardiomyocytes to repair the injury. The success of
reprogramming fibroblasts directly into cardiomyocyte-like
cells both in vitro and in vivo highlight the potential of this
approach for cardiac repair and regeneration. Direct
reprogramming would circumvent the need for the cell trans-
plantation that is required for stem cell therapy or approaches
involving iPSC-derived cardiomyocytes. Additionally, direct
reprogramming would circumvent the risk of potential terato-
genicity, which remains a concern with strategies utilizing
pluripotent cells and the clinical use of iPSC-derived
cardiomyocytes. However, safety issues related to genetic
modifications and viral vectors need to be resolved or small-
molecule pharmacological agents have to be discovered in
order to develop a safe strategy for direct reprogramming in
a clinical setting.
An ideal therapy forMI-induced cardiac injury would com-
bine the inhibition of reactive fibrosis (and other remodeling
processes) in non-infarcted areas with the induction of the
regeneration of the infarcted myocardium (Fig. 3), for exam-
ple , by d i rec t r ep rogramming of f ib rob las t s to
cardiomyocytes. A more detailed understanding of the gene
programmes, signaling cascades, and cellular metabolic routes
deciding between regeneration in neonatal rodents or scarring
and remodeling in adults is, however, critical for the develop-
ment of such therapeutics. A strong candidate to be included
in such a treatment strategy would be the inhibition of TGF-β
signaling, as it restricts adverse fibrotic remodeling and en-
hances cardiac reprogramming efficiency when combined
with cardiac transcription factor overexpression. Moreover,
the transcription factors that are central in cardiac develop-
ment and have been used in reprogramming fibroblasts to
cardiomyocytes also participate in mediating pathological ad-
aptation in the heart (Pikkarainen et al. 2004; Clowes et al.
2014). As more information concerning the structures and
molecular interactions of these factors is revealed (Luna-
Zurita et al. 2016), they are also expected to attract the atten-
tion of drug developers. Furthermore, our rapidly expanding
knowledge of the significance of non-coding RNAs in con-
trolling cardiac physiology and pathophysiology will possibly
bring forward novel approaches for the treatment of cardiac
fibrosis.
Fig. 3 Reparative response following a myocardial infarction. Hypoxia-
induced cardiomyocyte death leads to the activation of myofibroblasts
and a reparative fibrotic response in the injured area. Right top In adult
mammals, the fibrotic scar formed at the infarcted area is permanent and
promotes reactive fibrosis in the uninjured myocardium. Right bottom In
teleost fish and newts and in embryonic and neonatal mammals, the initial
formation of a fibrotic scar is followed by regeneration of the cardiac
muscle tissue. Induction of post-infarction cardiac regeneration in adult
mammals is currently the target of intensive research and drug discovery
attempts
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